More Stories

Informist, Thursday, May 21, 2026

NEW DELHI – Pharmaceutical major Eli Lilly and Co. Thursday said its experimental weight-loss drug retatrutide has delivered positive top line results from TRIUMPH-1, a phase three clinical trial in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes. Retatrutide is an investigational, first-in-class glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon triple hormone receptor agonist, the company said in a press release. 

At 80 weeks, four milligram, nine milligram, and 12 milligram doses of retatrutide met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss, the company said. 

For the primary endpoint, participants who took 9 milligram dose and 12 milligram dose of retatrutide lost an average of 29.2 kilogram or 25.9% of the body weight and 31.9 kilogram or 28.3% of the bodyweight, respectively, according to the press release. The participants who took 4 milligram dose of retatrutide, with just a single dose escalation step, lost an average of 21.4 kilogram or 19% of the body weight. 

Approximately 65.3% of participants took 12 milligram dose of retatrutide and achieved a body mass index under 30, falling under the threshold for obesity at 80 weeks. This includes 37.5% of the participants who started with class three obesity or body mass index above 40, said the company. In a pre-specified blinded extension, those participants with body mass index above 35, and who continued the 12 milligram dose of retatrutide to 104 weeks or two years lost an average of 38.5 kilogram or 30.3% of the body mass index. 

"Additionally, retatrutide showed significant improvements from baseline across certain cardiovascular risk factors, including waist circumference, non-high density lipoprotein cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein (hsCRP)," the company said. 

According to the company, the adverse effects seen were generally consistent with trials of other incretin-based therapies. The most common adverse events among participants treated with retatrutide were nausea, diarrhoea, constipation, vomiting, and upper respiratory tract infection, as per the press release. The incidences of dysaesthesia and urinary tract infections were generally mild to moderate, the company said. 

The discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, the press release said.  End

Reported by Astha Oriel

Edited by Akul Nishant Akhoury

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.